Baidu
map

Diabetic Med:对提供糖尿病教育和支持的卫生保健专业人员培训不足

2017-08-31 MedSci MedSci原创

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于糖尿病态度,愿望和需求(DAWN2)研究结果,指出了对提供糖尿病教育和支持的卫生保健专业人员培训不足。使用糖尿病态度,愿望和需求(DAWN2)研究的数据,研究为卫生保健专业人员提供糖尿病自我管理教育和培训的全球规范。研究人员共调查了17个国家的4785名护理糖尿病患者的卫生保健专业人员,以评估糖尿病保健服务,自我管理支持和培训

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于糖尿病态度,愿望和需求(DAWN2)研究结果,指出了对提供糖尿病教育和支持的卫生保健专业人员培训不足。使用糖尿病态度,愿望和需求(DAWN2)研究的数据,研究为卫生保健专业人员提供糖尿病自我管理教育和培训的全球规范。研究人员共调查了17个国家的4785名护理糖尿病患者的卫生保健专业人员,以评估糖尿病保健服务,自我管理支持和培训。

在接受调查的医疗保健专业人员中,有33.5%接受正式的自我管理研究生培训(国家占19.3-51.4%),62.9%接受了糖尿病医疗管理培训(47.6-70.6%的变异)。心理管理培训较低(19.1%),范围从3.6%至36.5%,20.4%(范围为国家占3.6-36.4%)的未接受研究生培训。总体而言,最大的培训需求是在糖尿病心理方面的管理(59.5%)。对于一些人来说,一个领域的培训与进一步培训的需求正相关。沟通技巧比如听力(76.9%)和鼓励问题(76.1%)的是最广泛使用的技能。讨论情感问题有限;不同国家的31-60%的医疗保健专业人员报告说,这仅在患者提起时才发生。大约三分之二的参与者报告说需要重大改善情绪/心理支持,但很少有人在这一领域接受过培训,而且在专业领域中有一致的发现。

目前的研究显示,医疗保健专业人员报告糖尿病自我管理教育水平不足,包括糖尿病患者的情绪和心理方面,许多人都没有在糖尿病管理的任何部分(包括医疗保健)接受研究生培训。

原始出处:

J. L. Byrne, M. J. Davies, I. Willaing,et al.Deficiencies in postgraduate training for healthcare professionals who provide diabetes education and support: results from the Diabetes Attitudes, Wishes and Needs (DAWN2) study

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760188, encodeId=44ea1e6018890, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 06 19:36:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048197, encodeId=9220204819e85, content=<a href='/topic/show?id=f4f220586fb' target=_blank style='color:#2F92EE;'>#专业人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20586, encryptionId=f4f220586fb, topicName=专业人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sat Feb 24 20:36:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771644, encodeId=06e71e7164415, content=<a href='/topic/show?id=1d503660007' target=_blank style='color:#2F92EE;'>#卫生保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36600, encryptionId=1d503660007, topicName=卫生保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054b38331488, createdName=minlingfeng, createdTime=Thu Feb 01 08:36:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638017, encodeId=fd04163801e06, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 01 08:36:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970518, encodeId=b56719e05183d, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Nov 21 08:36:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607991, encodeId=cb2d160e99151, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:36:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760188, encodeId=44ea1e6018890, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 06 19:36:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048197, encodeId=9220204819e85, content=<a href='/topic/show?id=f4f220586fb' target=_blank style='color:#2F92EE;'>#专业人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20586, encryptionId=f4f220586fb, topicName=专业人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sat Feb 24 20:36:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771644, encodeId=06e71e7164415, content=<a href='/topic/show?id=1d503660007' target=_blank style='color:#2F92EE;'>#卫生保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36600, encryptionId=1d503660007, topicName=卫生保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054b38331488, createdName=minlingfeng, createdTime=Thu Feb 01 08:36:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638017, encodeId=fd04163801e06, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 01 08:36:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970518, encodeId=b56719e05183d, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Nov 21 08:36:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607991, encodeId=cb2d160e99151, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:36:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760188, encodeId=44ea1e6018890, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 06 19:36:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048197, encodeId=9220204819e85, content=<a href='/topic/show?id=f4f220586fb' target=_blank style='color:#2F92EE;'>#专业人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20586, encryptionId=f4f220586fb, topicName=专业人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sat Feb 24 20:36:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771644, encodeId=06e71e7164415, content=<a href='/topic/show?id=1d503660007' target=_blank style='color:#2F92EE;'>#卫生保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36600, encryptionId=1d503660007, topicName=卫生保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054b38331488, createdName=minlingfeng, createdTime=Thu Feb 01 08:36:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638017, encodeId=fd04163801e06, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 01 08:36:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970518, encodeId=b56719e05183d, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Nov 21 08:36:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607991, encodeId=cb2d160e99151, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:36:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760188, encodeId=44ea1e6018890, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 06 19:36:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048197, encodeId=9220204819e85, content=<a href='/topic/show?id=f4f220586fb' target=_blank style='color:#2F92EE;'>#专业人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20586, encryptionId=f4f220586fb, topicName=专业人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sat Feb 24 20:36:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771644, encodeId=06e71e7164415, content=<a href='/topic/show?id=1d503660007' target=_blank style='color:#2F92EE;'>#卫生保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36600, encryptionId=1d503660007, topicName=卫生保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054b38331488, createdName=minlingfeng, createdTime=Thu Feb 01 08:36:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638017, encodeId=fd04163801e06, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 01 08:36:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970518, encodeId=b56719e05183d, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Nov 21 08:36:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607991, encodeId=cb2d160e99151, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:36:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760188, encodeId=44ea1e6018890, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 06 19:36:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048197, encodeId=9220204819e85, content=<a href='/topic/show?id=f4f220586fb' target=_blank style='color:#2F92EE;'>#专业人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20586, encryptionId=f4f220586fb, topicName=专业人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sat Feb 24 20:36:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771644, encodeId=06e71e7164415, content=<a href='/topic/show?id=1d503660007' target=_blank style='color:#2F92EE;'>#卫生保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36600, encryptionId=1d503660007, topicName=卫生保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054b38331488, createdName=minlingfeng, createdTime=Thu Feb 01 08:36:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638017, encodeId=fd04163801e06, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 01 08:36:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970518, encodeId=b56719e05183d, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Nov 21 08:36:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607991, encodeId=cb2d160e99151, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:36:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1760188, encodeId=44ea1e6018890, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 06 19:36:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048197, encodeId=9220204819e85, content=<a href='/topic/show?id=f4f220586fb' target=_blank style='color:#2F92EE;'>#专业人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20586, encryptionId=f4f220586fb, topicName=专业人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sat Feb 24 20:36:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771644, encodeId=06e71e7164415, content=<a href='/topic/show?id=1d503660007' target=_blank style='color:#2F92EE;'>#卫生保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36600, encryptionId=1d503660007, topicName=卫生保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054b38331488, createdName=minlingfeng, createdTime=Thu Feb 01 08:36:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638017, encodeId=fd04163801e06, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 01 08:36:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970518, encodeId=b56719e05183d, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Nov 21 08:36:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607991, encodeId=cb2d160e99151, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:36:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]

相关资讯

NEJM:利拉鲁肽可显著降低糖尿病肾病风险

研究表明,对于II糖尿病患者,服用利拉鲁肽可显著降低患者糖尿病肾病的发生和疾病进展

中国在全球率先开展干细胞教育治疗青少年发病1型糖尿病

8月30日下午,在中南大学湘雅二医院代谢内分泌科三病区病房里,来自美国纽约的1型糖尿病患儿Ivan正在接受干细胞教育治疗。作为全球首批接受该方法治疗的青少年发病1型糖尿病患者,经过前两个疗程的治疗后,Ivan病情明显好转。

J Periodontol:糖化胶原刺激牙龈成纤维细胞的分化

葡萄糖衍生的代谢物可能改变牙周膜中重要蛋白质的结构和生物学特性,如胶原蛋白。因此,胶原结合细胞可能改变其表型性状。虽然在牙周病变中可以检测到葡萄糖衍生物甲基乙二醛(MGO),胶质糖化对牙龈结缔组织生物学的精确影响尚未完全了解。本研究评估了MGO胶原糖化是否可能影响人类牙龈成纤维细胞(HGFs)的表型性质和重构能力。

Diabetic Med:预先存在的糖尿病是肾移植后细胞排斥反应率升高的危险因素?

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于预先存在的糖尿病是肾移植后细胞排斥反应率升高的危险因素的观察性队列研究。在一个很好的临床队列中,在现代免疫抑制的背景下,为了研究糖尿病患者是否有较高的肾移植排斥的风险。

Mol Ther:二苯并氮杂草衍生物有望成为糖尿病新希望!

普渡大学的研究人员进行的一项研究表明,褐变的特殊脂肪可以系统性的改善新陈代谢,dibenzazepine纳米颗粒的潜在作用。

Radiology:利用PET/MR进行全身成像在2型糖尿病的应用价值。

2型糖尿病原名叫成人发病型糖尿病,多在35~40岁之后发病,占糖尿病患者90%以上。2型糖尿病患者体内产生胰岛素的能力并非完全丧失,有的患者体内胰岛素甚至产生过多,但胰岛素的作用效果较差,因此患者体内的胰岛素是一种相对缺乏,可以通过某些口服药物刺激体内胰岛素的分泌。但到后期仍有一些病人需要使用胰岛素治疗。本研究旨在改善、评价和阐述利用全身成像序列评价胰岛素组织特异性介导18F- FDG的流入速率、

Baidu
map
Baidu
map
Baidu
map